Hims & Hers Fuels Growth via Market Expansion and New Care Verticals
Hims & Hers is preparing to expand further into hormonal health with offerings that target menopause and low testosterone, conditions representing a large U.S. market opportunity. Integrated lab testing and a broader shift toward longevity and preventive care are expected to increase patient lifetime value while positioning it as more than just a treatment provider. Instead, HIMS aims to play a role in long-term health optimization and proactive care.
International expansion is another powerful growth driver. The acquisition of ZAVA extends Hims & Hers' footprint across the U.K., Germany, France and Ireland, granting immediate access to more than 1.3 million existing patients and strengthening its position as a global digital health leader. Planned entry into Canada in 2026, aligned with the introduction of generic semaglutide, will likely make weight loss treatments significantly more affordable and accessible for a population where obesity rates remain high. Together, vertical integration, entry into new therapeutic categories and global expansion underscore Hims & Hers' capacity to sustain momentum and capture long-term market share.
LFMD & AMWL's Market Opportunities and Growth Drivers
LifeMD, Inc.'s LFMD market opportunity centers on scaling a vertically integrated, subscription telehealth platform across primary care and lifestyle conditions. LFMD is adding commercial insurance and Medicare coverage pathways, expanding reach and conversion. Growth drivers include LifeMD's owned pharmacy with planned non-sterile compounding, enabling cost and fulfillment control, a GLP-1 weight-management program with tens of thousands of subscribers and B2B partnerships for at-home labs and remote monitoring (Ash Wellness, Withings) that deepen personalization and retention. LifeMD's telehealth revenues grew 29.7% year over year in second-quarter 2025, underscoring sustained demand.
American Well Corporation's AMWL, popularly known as Amwell, market opportunity is tied to enterprise, payer and government modernization of care. Amwell's platform powers the Military Health System's virtual visits worldwide, replacing MHS Video Connect. This change has nearly tripled virtual visit volumes. A one-year extension sustains this presence across about 9.6 million beneficiaries. Amwell's growth drivers include increasing subscription software mix, new wins like Florida Blue and AI-enabled efficiency as it targets positive operating cash flow in 2026. Amwell continues positioning as a unified, tech-enabled care platform for large systems.
HIMS' Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 86.5% year to date, outperforming the industry's growth of 23.5%.
Image Source: Zacks Investment Research
HIMS' forward 12-month P/S of 3.8X is lower than the industry's average of 5.8X, but is higher than its three-year median of 2.4X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 137% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
American Well Corporation (AMWL) : Free Stock Analysis Report
Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report
LifeMD, Inc. (LFMD) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
5 minutes ago
- USA Today
Crushed by child care costs? Trump tax law offers parents some relief
Parents with crushing child care expenses will get a little more help in 2026, from Trump's new mega tax and spending law. The new tax law permanently increases the annual pre-tax contribution limit for dependent care flexible spending accounts, or DCFSAs, to $7,500 for married, joint filers. That's up from $5,000 and is the first change since 1986, apart from a temporary pandemic-era boost in 2021. It also expanded another tax provision, the child dependent care tax credit (CDCT), making up to 50% of a maximum of $3,000 of qualifying expenses reimbursable for one child and a $6,000 maximum for two or more. That means the maximum tax credit for one child increases to $1,500 from $1,050. Both changes can be good news for parents, but they should do the math to see which is more lucrative, accountants said. If your employer offers a DCFSA, the 'pre-tax dependent care FSA usually beats the dependent care credit' because of the higher contribution limit starting next year, said Richard Pon, a certified public accountant in San Francisco. Why a dependent care FSA may beat a credit Usually, a tax credit is more valuable than a tax deduction, which is what a pre-tax contribution to a dependent care FSA would be. A tax credit is a dollar-for-dollar reduction of your tax bill, and a deduction lowers your taxable income. For example, a $1,000 tax credit cuts your tax bill by $1,000. A $1,000 tax deduction for someone in the 22% tax bracket would result in $220 in tax savings ($1,000 x 0.22 = $220). But the maximum dependent care credit, in this case, phases out quickly and only applies to federal taxes. More: Trump's sweeping law increases child care tax credits. Here's how much and who benefits. 'In contrast, your payroll tax deduction reduces federal income tax, Social Security tax, Medicare tax and state tax,' Pon said. 'And there is no payroll phase-out…Your savings depends on your tax rate but with federal, state and 7.65% FICA (or Federal Insurance Contributions Act to fund Social Security and Medicare) taxes, your tax savings really adds up.' Additionally, a payroll deduction can reduce taxes paid in each pay period, which gives you more money throughout the year, said Sara Taylor, senior director of employee spending accounts at consulting firm WTW. 'On the tax credit side, it's a credit so there's no reduction in taxes you pay,' she said. 'It's just lowering what you owe when pay taxes. The benefit is delayed, and it does not increase your refund at all.' CDCT is a non-refundable tax credit, meaning it can reduce tax liability down to zero, but no refund is given if the credit exceeds tax liability. How do tax savings compare with DCFSA vs dependent care credit? Here's how the two tax changes compare for a family with two working parents, two children, $7,000 in qualified dependent care expenses during 2026, with adjusted gross income (AGI, or gross income minus certain deductions) of $60,000 and a marginal federal income tax rate of 22%: DCFSA CDCTC Can Americans use both provisions? Americans can use both the CDCTC and DCFSA, but it could be tough due to restrictions on each. The ability to leverage these options depends heavily on individual circumstances, such as income level, filing status, state and local tax implications, and the amount of qualified dependent care expenses. Beware, there are specific items that are considered qualified expenses, and the same expenses can't be used for both options. Potential pitfalls of DCFSA Tax savings are attractive with the DCFSA, but experts also issued a few warnings. What employers can do is raise the limit for less highly compensated employees and scale it back for those who earn more, Taylor said. All of this may take time, so many employers may not have this implemented for 2026, she said. To offer this benefit, employers must amend their plans by December 31, 2025. But 'this is so good for employees that I think most employers will adopt the higher benefit,' Taylor said. "But if your employer offers this benefit, I really encourage people look at that," she said. "This is an incredibly overlooked benefit.' If not, the DCTC is available to everyone, she said. Medora Lee is a money, markets and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday morning.
Yahoo
13 minutes ago
- Yahoo
Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 11 Best Short Squeeze Stocks to Buy Now. Following mixed results in the clinical trial of Ivonescimab, the company entered a new clinical collaboration with Revolution Medicines. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. The biopharma company, Summit Therapeutics Inc. (NASDAQ:SMMT) develops oncology therapies. Its lead candidate, Ivonescimab, targeting PD-1 and VEGF, is in clinical trials for non-small cell lung cancer. The Miami-based company currently holds regulatory collaborations for commercialization across multiple global regions. On May 30, 2025, Summit Therapeutics Inc. (NASDAQ:SMMT) announced mixed results from the trial of its antibody treatment for lung cancer, Ivonescimab. In a comparison study, the drug had initially performed better than Merck's Keytruda. But the latest evaluation revealed both promising and less favourable outcomes. Later, on June 30, 2025, the company entered a new clinical collaboration with Revolution Medicines to evaluate combinations of three RAS(ON) inhibitors with Ivonescimab in RAS mutant tumours. The aim is to assess the safety and efficacy of these combinations across three priority tumour types, including RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC). Initial study stands positive with evidence suggesting that Revolution Medicines' inhibitors in combination with a PD-1 antibody can deliver additive antitumor activity safely in patients with RAS mutant NSCLC. This has created anticipation for further therapeutic benefits with novel PD-1 bispecific inhibitors like Ivonescimab. With favorable developments triggering sharp upside movements, the company's short float of 25.63% remains attractive to short-squeeze investors. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon Disclosure. None.
USA Today
35 minutes ago
- USA Today
If you live in these states, your health care won't be as big or beautiful
Democratic-leaning states will feel more of the impact of sweeping Medicaid cuts included in the One Big Beautiful Bill Act, according to a new analysis by Oxford Economics. The report, authored by lead economist Barbara Denham, says that millions of Americans – regardless of where they live – will lose access to health insurance because of the tighter eligibility rules and new work requirements. Immigrants will be disproportionately affected, with many losing coverage under Medicaid, Medicare and the Children's Health Insurance Program. States such as California and New York – which have both expanded Medicaid and have large immigrant populations – are expected to be hit hardest. Other vulnerable states with large immigrant populations include Louisiana, Nevada, New Jersey, New Mexico and Washington, D.C. 'Federal funding cuts and the expiration of the Marketplace subsidies will have several economic consequences,' Denham wrote. 'The number of newly uninsured will rise significantly, putting more at risk of worse long-term well-being, which will sap productivity growth' States with the highest percentage of residents enrolled in Medicaid Unable to view our graphics? Click here to see them. The new law limits federal matching funds for noncitizens' medical care, shifting the financial burden to state governments and hospitals. That's particularly concerning for states with high percentages of foreign-born residents, many of whom rely on Medicaid. The federal cuts to Medicaid funding come at a time when states are looking to trim their spending, too. The Kaiser Family Foundation recently reported California has paused enrolling new immigrants in its health coverage program while Illinois has stopped state-funded health benefits for all immigrant adults between 42 to 64. States such as Idaho and Tennessee also enacted legislation limiting immigrant access to state health care benefits. States with the highest percentage of foreign-born residents Since 2012, 40 states and the District of Columbia have expanded Medicaid under federal initiatives. But with the expiration of marketplace subsidies and new restrictions on immigrant coverage, a handful of states now face the steepest declines in federal health care funding. Based on Oxford Economics' analysis of Congressional Budget Office and KFF data, more left-leaning states will lose more money per resident as the new law rolls out, but right-leaning Louisiana stands to lose the most ($5,855 per resident) of any state. Alabama, Florida, Georgia, South Carolina and Wyoming – states that didn't expand their Medicaid benefits – will see some of the smallest cuts. How much Medicaid funding each state is projected to lose per resident Some states have passed laws to buffer their residents or their budgets against federal cuts. For example: ◾ Their residents: New York, Missouri, Oklahoma, and South Dakota require coverage for adults earning up to 138% of the federal poverty line. ◾ Their budgets: Arizona, Arkansas, Illinois, Indiana, Montana, New Hampshire, North Carolina, Utah and Virginia tie Medicaid spending to federal funding levels.
